Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Journal Article
Overview
publication date
- March 17, 2022
has subject area
- Administration, Intravenous - Infusions, Intravenous
- Adult
- Alanine Transaminase
- Biological Factors - Factor VIII
- Biological Therapy - Genetic Therapy
- Blood Coagulation Disorders - Hemophilia A
- Blood Proteins - Factor VIII
- Coagulation Protein Disorders - Hemophilia A
- Dependovirus
- Environment and Public Health - Intention to Treat Analysis
- Genetic Diseases, Inborn - Hemophilia A
- Genetic Engineering - Genetic Therapy
- Genetic Vectors
- HIV Seronegativity
- Health Care Evaluation Mechanisms - Intention to Treat Analysis
- Hemorrhage
- Hemorrhagic Disorders - Hemophilia A
- Humans
- Infusions, Parenteral - Infusions, Intravenous
- Investigative Techniques - Intention to Treat Analysis
- Male
- Protein Precursors - Factor VIII
- Recombinant Fusion Proteins
Date in CU Experts
- December 11, 2025 2:29 AM
Full Author List
- Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon D; Wang J-D; Peerlinck K
author count
- 23
citation count
- 355
published in
- New England Journal of Medicine Journal
Other Profiles
International Standard Serial Number (ISSN)
- 0028-4793
Electronic International Standard Serial Number (EISSN)
- 1533-4406
Digital Object Identifier (DOI)
Additional Document Info
start page
- 1013
end page
- 1025
volume
- 386
issue
- 11